Genomic integration and gene expression by a modified adenoviral vector

Area of Science:

• Gene Therapy
• Molecular Biology
• Virology

Background:

• Adenoviral vectors are widely used for gene delivery due to their high titer and versatility.
• Retroviral vectors offer long-term gene expression and genomic integration capabilities.
• There is a need for vectors combining the advantages of both adenoviral and retroviral systems.

Purpose of the Study:

• To construct a replication-deficient recombinant adenovirus encoding luciferase.
• To evaluate the gene expression and integration capabilities of the novel vector in vitro and in vivo.
• To combine the high titer and versatility of adenoviral vectors with the long-term gene expression and integration of retroviral vectors.

Main Methods:

• Construction of a replication-deficient recombinant adenovirus using Moloney murine leukemia virus LTR sequences.
• Assessment of luciferase gene expression in cultured cells (in vitro) and animal models (in vivo).
• Determination of vector integration into host cell genomes using fluorescence in situ hybridization (FISH), gene walking, Southern hybridization, and polymerase chain reaction (PCR).

Main Results:

• Sustained gene expression was observed for up to three months in vivo in the submandibular gland, cortex, and caudate nucleus.
• The vector demonstrated random integration into the genomes of both dividing and nondividing cells.
• Integration occurred in the absence of transcomplementing reverse transcriptase or integrase activity.

Conclusions:

• The novel adenoviral vector effectively mediates long-term gene expression and genomic integration.
• This vector successfully merges the benefits of adenoviral and retroviral gene delivery systems.
• The developed vector holds significant potential for various gene therapy applications.